Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Nausea, Radiation Injuries, Vomiting

NCT01534637 2018-08-15

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Phase 2 Completed

22 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Nausea, Pancreatic Neoplasms, Vomiting

NCT01450826 2018-06-26

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Phase 2 Completed

136 enrolled 10 charts

CNS

Glioma, Nausea, Vomiting

NCT00381862 2017-06-12

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Phase 2 Completed

54 enrolled 7 charts

Gastrointestinal

Colonic Neoplasms, Nausea, Rectal Neoplasms, Vomiting, Colorectal Neoplasms

NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

Phase 2 Completed

20 enrolled 8 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

NCT02445872 2015-12-09

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Phase 2 Unknown

80 enrolled

Thoracic

Lung Neoplasms, Nausea, Vomiting

NCT00954941 2015-06-25

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Phase 2 Completed

100 enrolled 7 charts

MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Nausea, Vomiting, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT02407600 2015-04-03

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Phase 2 Unknown

150 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Nausea, Vomiting

NCT00212602 2012-06-14

ONO-7436 Phase II Study in Japan

Phase 2 Completed

420 enrolled

Nausea, Neoplasms, Vomiting

NCT01046461 2012-02-17

RAD

Phase 2 Unknown

41 enrolled

Nausea, Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT00169572 2010-05-10

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

Phase 2 Completed

492 enrolled

Nausea, Vomiting

Clinical Trials

The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Multi-day Doses in Prevention of Nausea and Emesis

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

ONO-7436 Phase II Study in Japan

RAD

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy